Breaking News

You are here » Indian-Commodity  :  Corporate  :  Avenue Supermarts' promoter sells 47.30 lakh shares

25-May2018

Avenue Supermarts' promoter sells 47.30 lakh shares

Avenue Supermarts' promoter Radhakishan Shivkishan Damani has offloaded 47.30 lakh shares of the company. The company's promoter has sold these shares at Rs 1,360.20 per share on the BSE on May 24, 2018.

Avenue Supermarts is a Mumbai-based company, which owns and operates DMart stores. D-Mart is an emerging national supermarket chain that offers customers a range of home and personal products under one roof.


Related News

View all news

IndiGo planning to launch one-stop flights to Europe: Report

InterGlobe Aviation (IndiGo) is reportedly planning to launch flights to London and other European cities by single stop. The airline is in talks with the airports in Tbilisi which is in Georgia and Baku......

Reliance Infrastructure reports 49% fall in Q2 consolidated net profit

Reliance Infrastructure has reported results for second quarter ended September 30, 2018.The company has reported a fall of 65.66% in its net profit at Rs 204.31 crore for the quarter under review as compared......

Shilpa Medicare gets tentative ANDA approval for Dimethyl Fumarate DR Capsules

Shilpa Medicare has received tentative approval for its ANDA for Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg. from USFDA. Dimethyl Fumarate Delayed Release Capsules 120 mg &......

Top News

View all news

Karnataka Bank launches CASA campaign

Karnataka Bank has launched Current & Savings Accounts campaign (CASA) of FY 2018-19 and introduced a new SB scheme 'KBL SB - TASC' a specialized product for Trusts/Associates/Societies/Clubs.Under......

M&M's arm opens manufacturing hub in Bengaluru

Mahindra & Mahindra's (M&M) subsidiary -- Mahindra Electric Mobility has opened its electric technology manufacturing hub set up with an investment of Rs 100 crore in Bengaluru. The plant......

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific......